Objective To investigate the effect of dapagliflozin on urinary protein in elderly patients with type 2 diabetic nephropathy complicated with hypertension. Methods 186 elderly patients with type 2 diabetic nephropathy (DKD) admitted to The First Affiliated Hospital of Zhengzhou University from December 2018 to December 2019 were observed. All the enrolled patients had hypertension. According to whether dapagliflozin was given, the patients were divided into two groups: dapagliflozin group (93 patients were treated with dapagliflozin 10mg) and control group (93 patients were treated with conventional drugs other than SGLT2i).Hemoglobin A1c (HbA1c), blood pressure, baseline body weight or BMI, 24-hour urinary protein, urinary albumin creatinine ratio (UACR) and glomerular filtration rate (eGFR) were completed at first admission. Results of these indicators were observed 1 year later in both groups. Results The UACR, SBP and BMI of the dapagliflozin group were significantly lower than those of the control group after 1 year of treatment, and the differences were statistically significant(P＜0.05). In the analysis of primary endpoint events that occurred within 1 year, the dapagliflozin group had a significant protective effect compared with the control group (HR=0.157,95%CI 0.046-0.538,P＜0.05).There was no significant difference in cumulative urinary and lower limb amputation events at 1 year between the two groups (HR=0.901,95%CI0.383-2.121,P＞0.05). Conclusion Dapagliflozin can effectively reduce urinary protein excretion and protect renal function in elderly patients with type 2 diabetic nephropathy complicated with hypertension.